• Jose Manuel Calvo Villas.
• Servicio de Hematología y Hemoterapia, Hospital Universitario Miguel Servet, Zaragoza, España. Electronic address: jmcvillas@hotmail.com.
• Med Clin (Barc). 2019 May 17; 152 (10): 397-404.

AbstractTumour lysis syndrome (TLS) is a life-threatening emergency characterised by a massive cytolysis with the release of intracellular electrolytes, nucleic acids, and metabolites into the circulation. TLS comprises laboratory derangements (hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia) responsible for acute kidney injury. In patients with hematologic malignancies after cytotoxic therapy or spontaneously and also in advanced solid tumours. Assessment of disease specific risk level for TLS in patients receiving anti-tumoural therapy is essential for early diagnosis. Prophylaxis is the mainstay of management of TLS. It is important to routinely initiate a risk-adapted prophylactic strategy to correct metabolic alterations and preserve renal function. High and intermediate risk patients and patients with established TLS should be managed with multidisciplinary medical care in a hospital unit to receive monitoring and medical care. Renal replacement therapy should be considered in patients with refractory TLS.Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

36 keywords...

hide…